💨 Abstract

Remidio, a global leader in AI-powered ophthalmic solutions, has invested in Occuity, a UK-based developer of handheld, non-contact, non-invasive, and consumable-free optical screening devices. This strategic move aims to position Remidio at the forefront of non-invasive systemic disease screening, with a focus on India's growing myopia epidemic.

Courtesy: theprint.in

Summarized by Einstein Beta 🤖